Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Navelbine Promising as a Radiosensitizer in Non-Small-Cell Lung Cancer

August 1, 1995
Publication
Article
OncologyONCOLOGY Vol 9 No 8
Volume 9
Issue 8

The use of the anticancer agent vinorelbine (Navelbine) as a radiosensitizerto enhance the effectiveness of radiation treatment is suggested

The use of the anticancer agent vinorelbine (Navelbine) as a radiosensitizerto enhance the effectiveness of radiation treatment is suggestedby a preclinical study reported at the annual meeting of the AmericanAssociation of Cancer Research (AACR). Timing and cell cycle dependencyappear to be two critical factors in producing the combination'seffects.

In this preclinical study, vinorelbine appeared to be more effectivewhen administered after radiation rather than prior to radiation.In addition, vinorelbine showed the most significant impact whenirradiated cells were exposed to the drug after they had plateauedin the G2-M phase of the cell cycle.

The in vitro study evaluated the ability of vinorelbine to potentiatethe effect of radiotherapy in the treatment of non-small-celllung cancer (NSCLC) in the human cell line NCI-H460. Based onthe results, researchers concluded that the combination meritsclinical study.

"The purpose of this study was to determine if radiation...mightbe more effective when combined with Navelbine, considering thedrug's efficacy in non-small-cell lung cancer," said DavidDuch, PhD, of Burroughs Wellcome Co., manufacturer of Navelbine."We demonstrated that Navelbine may act as a potentiatorof radiation and enhance radiation's role in blocking cell division."

When cells were exposed to vinorelbine for 24 hours and then irradiatedat doses ranging from 1 to 8 Gy, the effect on the cells was dose-dependent.Radiation administered at 1 Gy combined with vinorelbine showeda 1.7-fold increase in blocking cell division over radiation alone;6 Gy of radiation combined with vinorelbine had more than a 5-foldincrease in blocking cell division over radiation alone.

The study also reversed the treatment sequence by administeringradiation first and then exposing the cells to vinorelbine. Similarsurvival ratios were obtained at concentrations of vinorelbinethat were 10-fold lower than those given prior to radiation.

"When we saw that Navelbine worked better after radiation,we examined its mechanism of action and determined that its effectivenessdepended on what radiation had already done in the cell cyclein terms of blocking cell division," said Dr. Duch. "Cellstreated with radiation become blocked in the G2-M phase of thecell cycle. We found that when we waited to add Navelbine untilmost of the treated cells were blocked at this stage, optimalpotentiation was observed, and that Navelbine was not effectivewhen administered prior to this time."

Radiation produced a maximum 60% to 70% block in the G2-M phaseof the cell cycle after 10 hours. Vinorelbine given early afterirradiation, when only 10% to 30% of the cells were in G2-M, producedcell survival ratios similar to the controls treated with radiationalone.

Articles in this issue

Many Factors Prevent Women With Breast Cancer Symptoms From Seeking Medical Help Quickly
Sociobiology and Cervical Cancer
Book Review: Cambridge Medical Reviews--Haematologic Oncology, Volume 3
Cigarette Smoking Among Adults--United States, 1993
Navelbine Promising as a Radiosensitizer in Non-Small-Cell Lung Cancer
Phase II Study Shows That Significantly Fewer rhIL-11 Treated Patients Require Platelet Transfusions
Differences in Structural Proteins in Prostate Cells May GiveEarly Indications of Cancer
New Lymphatic Mapping May Avoid Many Axillary Dissections
Radiation After Prostatectomy Keeps Some Patients Disease Free Longer
Commentary (Moulin): Diagnosis and Management of Brachial Plexus Lesions in Cancer Patients
Commentary (Kinsella): Current Status of Radiation Sensitization by Fluoropyrimidines
Commentary (Pritchard): Current Status of Vinorelbine For Breast Cancer
Diagnosis and Management of Brachial Plexus Lesions in Cancer Patients
Current Status of Vinorelbine For Breast Cancer
Commentary (Rich): Current Status of Radiation Sensitization by Fluoropyrimidines
Recent Videos
Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
Patients who face smoking stigma, perceive a lack of insurance, or have other low-dose CT related concerns may benefit from blood testing for lung cancer.
Related Content
Advertisement

HITOCH After Surgery Appears Safe, May Improve Survival in Mesothelioma

HITOCH After Surgery Appears Safe, May Improve Survival in Mesothelioma

Tim Cortese
May 6th 2025
Article

A systematic review shows that patients with mesothelioma who received HITOCH experienced between 13 to 35 months of survival.


Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

Exploring the Value of Preoperative CAPTEM in Atypical Lung NETs

Georgios Evangelou, MD, MSc
September 16th 2024
Podcast

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.


Chemoimmunotherapy-Enhanced Survival vs Chemotherapy Alone in ES-SCLC

Chemoimmunotherapy-Enhanced Survival vs Chemotherapy Alone in ES-SCLC

Tim Cortese
April 27th 2025
Article

Patients with ES-SCLC who received immunotherapy plus chemotherapy experienced a median OS of 14.9 months vs 11.9 months with chemotherapy alone.


Rian M. Hasson Charles, MD, MPH, FACS, discusses advances in equitable lung cancer screening and her experiences as a woman in thoracic oncology.

Achieving Health Equity in Lung Cancer Surgery

Rian M. Hasson Charles, MD, MPH, FACS
April 1st 2024
Podcast

Rian M. Hasson Charles, MD, MPH, FACS, discusses advances in equitable lung cancer screening and her experiences as a woman in thoracic oncology.


A systematic review shows that well-designed randomized clinical trials are necessary to optimize treatment strategies with tislelizumab in lung cancer.

Tislelizumab Significantly Boosts Survival in Lung Cancer Trials

Russ Conroy
April 23rd 2025
Article

A systematic review shows that well-designed randomized clinical trials are necessary to optimize treatment strategies with tislelizumab in lung cancer.


“These results and the lack of systemic toxicity observed with [TTFields] provide patients with a promising new treatment option,” according to Joachim Aerts, MD, an investigator of the phase 3 LUNAR trial (NCT02973789).

TTFields Therapy Earns EU Approval in Metastatic Non–Small Cell Lung Cancer

Russ Conroy
April 23rd 2025
Article

Data from the phase 3 LUNAR trial support the Conformité Européenne Mark for tumor treating fields in metastatic non–small cell lung cancer.

Related Content
Advertisement

HITOCH After Surgery Appears Safe, May Improve Survival in Mesothelioma

HITOCH After Surgery Appears Safe, May Improve Survival in Mesothelioma

Tim Cortese
May 6th 2025
Article

A systematic review shows that patients with mesothelioma who received HITOCH experienced between 13 to 35 months of survival.


Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

Exploring the Value of Preoperative CAPTEM in Atypical Lung NETs

Georgios Evangelou, MD, MSc
September 16th 2024
Podcast

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.


Chemoimmunotherapy-Enhanced Survival vs Chemotherapy Alone in ES-SCLC

Chemoimmunotherapy-Enhanced Survival vs Chemotherapy Alone in ES-SCLC

Tim Cortese
April 27th 2025
Article

Patients with ES-SCLC who received immunotherapy plus chemotherapy experienced a median OS of 14.9 months vs 11.9 months with chemotherapy alone.


Rian M. Hasson Charles, MD, MPH, FACS, discusses advances in equitable lung cancer screening and her experiences as a woman in thoracic oncology.

Achieving Health Equity in Lung Cancer Surgery

Rian M. Hasson Charles, MD, MPH, FACS
April 1st 2024
Podcast

Rian M. Hasson Charles, MD, MPH, FACS, discusses advances in equitable lung cancer screening and her experiences as a woman in thoracic oncology.


A systematic review shows that well-designed randomized clinical trials are necessary to optimize treatment strategies with tislelizumab in lung cancer.

Tislelizumab Significantly Boosts Survival in Lung Cancer Trials

Russ Conroy
April 23rd 2025
Article

A systematic review shows that well-designed randomized clinical trials are necessary to optimize treatment strategies with tislelizumab in lung cancer.


“These results and the lack of systemic toxicity observed with [TTFields] provide patients with a promising new treatment option,” according to Joachim Aerts, MD, an investigator of the phase 3 LUNAR trial (NCT02973789).

TTFields Therapy Earns EU Approval in Metastatic Non–Small Cell Lung Cancer

Russ Conroy
April 23rd 2025
Article

Data from the phase 3 LUNAR trial support the Conformité Européenne Mark for tumor treating fields in metastatic non–small cell lung cancer.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.